WELLBUTRIN XL Drug Patent Profile
✉ Email this page to a colleague
When do Wellbutrin Xl patents expire, and when can generic versions of Wellbutrin Xl launch?
Wellbutrin Xl is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in WELLBUTRIN XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wellbutrin Xl
A generic version of WELLBUTRIN XL was approved as bupropion hydrochloride by SENORES PHARMS on February 7th, 2000.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for WELLBUTRIN XL?
- What are the global sales for WELLBUTRIN XL?
- What is Average Wholesale Price for WELLBUTRIN XL?
Summary for WELLBUTRIN XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 85 |
| Patent Applications: | 1,768 |
| Drug Prices: | Drug price information for WELLBUTRIN XL |
| What excipients (inactive ingredients) are in WELLBUTRIN XL? | WELLBUTRIN XL excipients list |
| DailyMed Link: | WELLBUTRIN XL at DailyMed |
Recent Clinical Trials for WELLBUTRIN XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 1 |
| Mclean Hospital | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
Pharmacology for WELLBUTRIN XL
| Drug Class | Aminoketone |
| Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
| Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Paragraph IV (Patent) Challenges for WELLBUTRIN XL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| WELLBUTRIN XL | Extended-release Tablets | bupropion hydrochloride | 150 mg and 300 mg | 021515 | 1 | 2004-09-21 |
US Patents and Regulatory Information for WELLBUTRIN XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | AB3 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | AB3 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for WELLBUTRIN XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | 6,096,341 | ⤷ Start Trial |
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | 6,096,341 | ⤷ Start Trial |
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | 6,143,327 | ⤷ Start Trial |
| Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | 6,143,327 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
